Literature DB >> 22641733

Trials (and tribulations) of biocompatible peritoneal dialysis fluids.

David W Johnson1, Yeoungjee Cho, Fiona G Brown.   

Abstract

Mesh：

Substances：

Year:  2012        PMID： 22641733      PMCID： PMC3525429          DOI： 10.3747/pdi.2012.00044

Source DB:  PubMed          Journal:  Perit Dial Int        ISSN： 0896-8608            Impact factor:   1.756


× No keyword cloud information.
  33 in total

Review 1.  Neoangiogenesis in the peritoneal membrane.

Authors:  R T Krediet; M M Zweers; A C van der Wal; D G Struijk
Journal:  Perit Dial Int       Date:  2000       Impact factor: 1.756

2.  Clinical effects of a peritoneal dialysis regimen low in glucose in new peritoneal dialysis patients: a randomized crossover study.

Authors:  Caatje Y le Poole; Frans J van Ittersum; Marcel C Weijmer; Rob M Valentijn; Piet M ter Wee
Journal:  Adv Perit Dial       Date:  2004

Review 3.  Clinical indices of in vivo biocompatibility: the role of ex vivo cell function studies and effluent markers in peritoneal dialysis patients.

Authors:  Ruth Mackenzie; Clifford J Holmes; Suzanne Jones; John D Williams; Nicholas Topley
Journal:  Kidney Int Suppl       Date:  2003-12       Impact factor: 10.545

Review 4.  In vitro biocompatibility performance of Physioneal.

Authors:  Catherine M Hoff
Journal:  Kidney Int Suppl       Date:  2003-12       Impact factor: 10.545

Review 5.  Effect of different buffers on the biocompatibility of CAPD solutions.

Authors:  H T Schambye
Journal:  Perit Dial Int       Date:  1996       Impact factor: 1.756

6.  A long-term study of a bicarbonate/lactate-based peritoneal dialysis solution--clinical benefits. The Bicarbonate/Lactate Study Group.

Authors:  A Tranaeus
Journal:  Perit Dial Int       Date:  2000 Sep-Oct       Impact factor: 1.756

7.  Changing prescribing practice in CAPD patients in Korea: increased utilization of low GDP solutions improves patient outcome.

Authors:  Ho Yung Lee; Hoon Young Choi; Hyeong Cheon Park; Bo Jeung Seo; Jun Young Do; Sung Ro Yun; Hyun Yong Song; Yeong Hoon Kim; Yong-Lim Kim; Dae Joong Kim; Yong Soo Kim; Moon Jae Kim; Sug Kyun Shin
Journal:  Nephrol Dial Transplant       Date:  2006-09-06       Impact factor: 5.992

8.  Long-term exposure to new peritoneal dialysis solutions: Effects on the peritoneal membrane.

Authors:  Siska Mortier; Dirk Faict; Casper G Schalkwijk; Norbert H Lameire; An S De Vriese
Journal:  Kidney Int       Date:  2004-09       Impact factor: 10.612

9.  The Euro-Balance Trial: the effect of a new biocompatible peritoneal dialysis fluid (balance) on the peritoneal membrane.

Authors:  John D Williams; Nicholas Topley; Kathrine J Craig; Ruth K Mackenzie; Monika Pischetsrieder; Cristina Lage; Jutta Passlick-Deetjen
Journal:  Kidney Int       Date:  2004-07       Impact factor: 10.612

Review 10.  Glucose degradation products in peritoneal dialysis fluids: do they harm?

Authors:  Janusz Witowski; Achim Jörres; Katarzyna Korybalska; Krzysztof Ksiazek; Justyna Wisniewska-Elnur; Thorsten O Bender; Jutta Passlick-Deetjen; Andrzej Breborowicz
Journal:  Kidney Int Suppl       Date:  2003-05       Impact factor: 10.545
View more
  3 in total

1.  The balANZ study--strengthening the evidence for neutral-pH solutions low in glucose degradation products.

Authors:  Martin Wilkie
Journal:  Perit Dial Int       Date:  2012 Sep-Oct       Impact factor: 1.756

2.  Is the Effect of Low-GDP Solutions on Residual Renal Function Mediated by Fluid State? An Enigmatic Question which Still Needs to be Solved.

Authors:  Jeroen P Kooman; Tom Cornelis; Frank M van der Sande; Karel M L Leunissen
Journal:  Perit Dial Int       Date:  2016 May-Jun       Impact factor: 1.756

3.  Biocompatibility of a new PD solution for Japan, Reguneal™, measured as in vitro proliferation of fibroblasts.

Authors:  Bart Dioos; Goedele Paternot; Rose-Marie Jenvert; Annick Duponchelle; Mark R Marshall; Migaku Nakajima; Edward Ramirez Ganoza; James A Sloand; Anders P Wieslander
Journal:  Clin Exp Nephrol       Date:  2018-06-20       Impact factor: 2.801
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.